LLY - Eli Lilly and • Financials

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2016	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2017	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2018	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2019	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	34,124	7,984	-	15%	5.8	10,772	49%	22,298	2.8	3,611	-7,392	3,496	-3,781	-750	-4,069	78%	0.775%
12/2024	45,043	14,666	-	24%	12	14,272	74%	30,221	2.1	8,172	-8,404	1,230	-232	-2,500	-4,680	44%	0.674%
12/2025	65,179	28,299	-	32%	23	26,535	78%	35,235	1.3	16,187	-10,849	-2,213	5,338	-4,108	-5,384	26%	0.558%

To see all financials—including updated, you must be Premium.